Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Sound waves vs. scalpel: new study tests shockwave therapy for blocked leg arteries

NCT ID NCT06829914

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares a new, less invasive shockwave device to standard surgery for treating severe calcium buildup in the main leg artery. The shockwave uses sound waves to break up the calcium, while surgery involves physically removing the blockage. Researchers want to see if the shockwave is as safe and effective as surgery for improving blood flow and preventing future problems. The trial involves 60 people with severe leg pain or tissue damage due to blocked arteries.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Shockwave catheter (a device that uses sound waves to break up calcium in arteries)
What this could lead to
If successful, this could offer a less invasive alternative to surgery for people with severely blocked leg arteries, potentially reducing recovery time and complications.
What could go wrong
This is a small, early-stage study with only 60 participants, so results may not apply to everyone. The shockwave procedure may not be as durable as surgery, and there is a risk of artery damage or blockage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2024

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: A patient will be eligible for inclusion in this study if he or she meets all of the following criteria (confirmed by core lab): 1. CFA atherosclerotic stenosis 60-100% 2. Moderate to severe calcification reported on imaging 3. Lifestyle-limiting intermittent claudication (IC) or chronic limb-threatening ischemia (CLTI) as described by Rutherford chronic limb ischemia (CLI) category 2-5 4. Failing conservative therapy 5. Operative candidate for CFE prior to enrollment 6. ≥18 years of age Exclusion Criteria: A patient will be ineligible for inclusion in this study if he or she meets any of the following criteria: 1. History of CFE or bypass in affected limb 2. Thrombosis of affected CFA 3. Aneurysm in the common femoral artery of target limb 4. Known target lesion restenosis (re-narrowing of the artery to ≥50% following the alleviation of a previous narrowing within 3 months) 5. Any preceding percutaneous cardiovascular intervention within 2 weeks 6. Inability to tolerate DAPT 7. Known coagulopathy or bleeding diathesis, thrombocytopenia with platelet count \<100,000/µL 8. Uncontrolled diabetes (HbA1c ≥10.0%) 9. Non-ambulatory 10. Extensive tissue loss requiring amputation or salvageable only with complex foot reconstruction or non-traditional transmetatarsal amputations 11. MI within 6 weeks (defined as presumed ischemic symptoms (chest pain, ST-segment deviation and troponin higher than 2 times the upper limit of normal)) 12. Stroke within 3 months (defined as sudden transient or irreversible focal neurological deficit resulting from a cerebrovascular cause) 13. Pregnant

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Calcification; heart are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Baylor Scott & White The Heart Hospital - Plano

    Plano, Texas, 75093, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.